(Q42607649)

3 November 2017

title

Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Finasteride Urodynamics Study Group (English)

1 reference

3 November 2017

Schäfer W

1

1 reference

3 November 2017

Tammela TL

2

1 reference

3 November 2017

Barrett DM

3

1 reference

3 November 2017

Abrams P

4

1 reference

3 November 2017

Hedlund H

5

1 reference

3 November 2017

Rollema HJ

6

1 reference

3 November 2017

Nordling J

7

1 reference

3 November 2017

Andersen JT

8

1 reference

3 November 2017

Hald T

9

1 reference

3 November 2017

Matos-Ferriera A

10

1 reference

3 November 2017

Bruskewitz R

11

1 reference

3 November 2017

Miller P

12

1 reference

3 November 2017

Mustonen S

13

1 reference

3 November 2017

Cannon A

14

1 reference

3 November 2017

Malice MP

15

1 reference

3 November 2017

Jacobsen CA

16

1 reference

3 November 2017

Bach MA

17

1 reference

3 November 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

3 November 2017

1 reference

3 November 2017

volume

54

1 reference

3 November 2017

issue

2

1 reference

3 November 2017

page(s)

278-283

1 reference

The development of human benign prostatic hyperplasia with age

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Development of canine benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

The clinical development of a 5α-reductase inhibitor, finasteride

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Urodynamic effects of finasteride in the treatment of bladder outlet obstruction due to benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

The Assessment of Prostatic Obstruction from Urodynamic Measurements and from Residual Urine

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Urodynamic and Clinical Effects of Terazosin Therapy in Patients with Symptomatic Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Doxazosin in men with lower urinary tract symptoms: urodynamic evaluation at 15 months

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900130-2

7 January 2021

10.1016/S0090-4295(99)00130-2

Identifiers

DOI

1 reference

3 November 2017

1 reference